MedTrace Logo

Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization

NCT03072082 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2017-04-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether Danlou Tablet is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

Conditions

  • Coronary Artery Disease(CAD)

Interventions

DRUG

Danlou Tablet

Conventional western medicine \& Danlou Tablet

DRUG

DanLou Tablet placebo

Conventional western medicine \& placebo (for Danlou Tablet)

DRUG

Aspirin Enteric-coated Tablets

100 mg tablet, one tablet daily.

DRUG

Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet

One tablet daily. (for patients who can't use aspirin)

DRUG

Atorvastatin calcium

10 mg tablet, two tablets each night.

DRUG

Isosorbide Mononitrate Tab 20 MG

One tablet two times daily.

DRUG

Metoprolol Tartrate Tab 25 MG

12.5 mg or 25 mg two times daily.

DRUG

Trimetazidine Dihydrochloride Tablets

20 mg tablet, one tablet three times daily.

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences

    collaborator OTHER

  • Jun Li

    lead OTHER

Principal Investigators

  • Jie Wang, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2018-12-31
Completion
2019-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03072082 on ClinicalTrials.gov